SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (9476)5/25/2006 1:49:31 AM
From: RCMac  Read Replies (1) of 10280
 
Finally, Pfizer wouldn't have to resolve anything with Neurocrine in order to make a deal with Sepracor, would they?

Not with NBIX -- I can't imagine the license agreement includes anything that would impede PFE from anything much; even the provisions that kept PFE from munching NBIX dropped away after less than a year.

But PFE would need to make a deal with the FTC, which would surely frown on PFE from having both Indiplon and Lunesta.

Recall that when PFE acquired Warner-Lambert 6-7 years ago, PFE had to give up one of two early development stage cancer drugs with similar methods of action, and chose to return PFE's rights to Tarceva to OSIP, and to retain the other, which later failed.

One way to satisfy the FTC would be to return to NBIX the rights to Indiplon . . . . .
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News